drugset
drugset / Trial / NCT00195247

Study Evaluating TTI-237 in Advanced Malignant Solid Tumors

NCT00195247 ↗

Phase 1 Terminated 45 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
Non-randomizedFactorialOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of TTI-237 for the treatment of subjects with advanced malignant solid tumors.

Timeline

Start
2005-05
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject CEVIPABULIN Small molecule — Intravenous

Indications

neoplasm